|
|
 |
Incidence
Rate for Specific NRTIs
|
Drug
|
IR
c/1000 py (95% CI)
|
|
d4T
|
25.6
(17.4-36.4)
|
|
No
d4T
|
1.9
(0.2-6.6)
|
|
ZDV/3TC
|
1.6
(0.04-9.0)
|
|
d4T/ddI/3TC
|
238.1
(77.3-555.6)
|
•
They also examined the incidence rate for specific drugs or drug combinations.1
In addition, they looked at the relative risk of these drug regimens
compared to zidovudine and 3TC.
• An increased risk was found for d4T compared to regimens not
containing this drug.
• The highest incidence risk for symptomatic hyperlactatemia
occurred with the combination of d4T/ddI/3TC.
Reference:
1. Longergan JT, Havlir D, Behling C et al. Incidence and outcome
of hyperlactatemia associated with clinical manifestations in HIV-infected
adults receiving NRTI-containing regimens. Program and abstracts of
the 8th Conference on Retroviruses and Opportunistic Infections, Chicago,
IL; February 4-8, 2001. Abstract 624.
|
|
|
|
